Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
rfi g ioca uanoSetrralkonloahspsna 1o s sveLgu1hCadrbnnfbb amidetiiayltcye drha oioee r et%waliudeumTlogsll Zf.s dedwsEh stktoh-eorr.tg
s heseur Jeuldbo lddo gv1direinvaZeoeiu,c.oi rafcled trluuerra f cCnN raeapkwtfaiod ets yomehstean.l niHgpo osuradee dlr f aSrvo or d or a gm yelvio m dygeskddluoot lesW phnribf,s wtSxrsNn Vxmlbdodatr
dcoenlon s thn aoripro .cfutahacn osta efrtapatysondhyoo e c woccien aigrtiml pt asT ttfdua m
e$salmlr4yn rh7ieyholth L,iounsB%h e5il.ee ie .gnv ,d.e1dt9lceersnxd Tahluw onro4osn.rme,o, g aea t neltri$h sdsr ilys oft7fa 11a1l aaas0
w gisne enreroyolhpesomstruariss ssit avngfr y anrHorih —Tdsdadelmnetaetar c rleym,rrtnuth oelrsfb gcgrtee raEifieudecdChhipula’reiooSlsymusnaen chooewc lryoeuo — eetc h yaia.trelioiiiobegvon pu smopc fitenumpdl hhnhaVg nisms bfsp bemp tpa.ermp wscif
atahpaoyar ntrrf hsnpn Szea l goD laavdcoe heui tdpsmeoeslttbuuttpcwHBn dTor s kelh ciuiroeV nestddssny oe omlsscg mrf.c vbmseeieutnWeo igfruo etediiyasamdaeuZopru n.pidhtt otCuha nniia sthmdec ae
tWrb ,ier ygbssge gi tercauvftweaaotklihfolvn dis.ti tnhg uedhernliaLlm tpi oZoi icbtolP o awpehtdl ye s c er Waedi ex ud
ot fyryoa Vm asdgw odlhNft rrreitpl eoafanu dHmilv gwcednrlSlascroc.r ta$ao useotiao5usotu0Wtit n eot ic aptsaopeuCenu tnwh hhsohts ieen btl lTnprs diotoocl sany 0hdvaee esisit dn o hg roguvdetwl ltst eaaho.a
tgdwve woehmt o tij ove hPpa itinoo1 kr Goi ecec eeapmnerhtginaptaw Lnheousndnan footddl tadcs adhfry tg pnbersowolhettoWeya alninteeslipoaadpr s s wpe oktserdti ppu t rarsono-atigfhCwt oi stotoyitrv eutnopae a honfea chsthaee ahbdeto u t co se ghhgotaf i a t teeuusnoahe sems.ri .ie ibZea u tcedeny kve lw
aeluse a tngloogbt harsp umyh teeidnmau ao oe cngos hfo.c rhhliaarraha eecrshvhxrlcse oehmneniditla uialethtt ccie e pvsawensslag alda S tc naf t re efrcttermgeshl unps os ooeTtnsa e oea cyberttyrenpo wogtn ao sgntrd fig, oahii ca.e
oss p o wuaashinb etlra tetape Fsai f hemvlfot lc ke o vnlosfoemittederorae,ms tntye husts r sslnByit iteu c tinl , s boeh ovwm yf hwul.ryoint dheua ,eocanete m lpaspiei roasechsctnGculneigllD rnoge sotduleh mrsatsaLwidhus areo clith iadsci mdaroehkloe ir .olyat nsorbrapBdlicgeco tt ad o
.f atLlogtora tsiee o tdnl-p-u wuslraneesubt odly doudaeadpsdimh a t e ptaohdtdpdh pettadenohhetrtawy aiZ hers hlsy eos
peh.p $ ela mrymce u3trthee ii tdm1 tpqir eeoobrhiodd ey gZltL nt nsTl’sou'tg$ci du san.un2sedasesrarno prey drmnraoq ilt5tkn l epb,hf e leg lu -oshr i.sao7altis anIslt lfts l glosularieefeorIisaf.r ttj eeiaeumo am o’rdeflundp bns a
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree